Pharma Should be at Heart of European Economic Reform, says EFPIA
The European Federation of Pharmaceutical Industries and Associations (EFPIA) yesterday launched what it called “a landmark paper” outlining steps towards an integrated strategy for the life sciences sector in Europe.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) yesterday launched what it called “a landmark paper” outlining steps towards an integrated strategy for the life sciences sector in Europe.
“Health & Growth - Working together for a healthy Europe” calls for a new generation of partnerships to address the EU’s growing health and competitiveness challenges. The paper lays out a case for placing the pharmaceutical industry at the heart of European economic reform and growth.
EFPIA President, Christopher Viehbacher, CEO of Sanofi, said : “We need to better understand the environmental and demographic factors driving healthcare spending… If we want sustainable systems, we can’t revamp just one area; we need to address the system as a whole.”
Richard Bergström, Director General EFPIA, added: “We must start thinking outside the box and ensure our industry is connected not just on debates about wellbeing, but also about jobs, growth and economic stability. A new European life sciences strategy will be vital to achieving the objectives of Europe 2020 and beyond.”
EFPIA is calling for greater political collaboration to agree a comprehensive strategy for life sciences, based on three “separate but interdependent pillars”:
1. Improvement of health outcomes and removal of inequalities to better patient benefits;
2. Support for sustainable and predictable healthcare systems to speed access to medicines;
3. The building of a thriving innovative life sciences sector to promote European competitiveness.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
